GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » EV-to-EBIT

Ablynx NV (XBRU:ABLXS) EV-to-EBIT : -0.01 (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Ablynx NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ablynx NV's Enterprise Value is €0.97 Mil. Ablynx NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2017 was €-101.11 Mil. Therefore, Ablynx NV's EV-to-EBIT for today is -0.01.

The historical rank and industry rank for Ablynx NV's EV-to-EBIT or its related term are showing as below:

XBRU:ABLXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.5   Med: -9.1   Max: 186.1
Current: -32.61

During the past 12 years, the highest EV-to-EBIT of Ablynx NV was 186.10. The lowest was -40.50. And the median was -9.10.

XBRU:ABLXS's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 10.295 vs XBRU:ABLXS: -32.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ablynx NV's Enterprise Value for the quarter that ended in Dec. 2017 was €0.00 Mil. Ablynx NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2017 was €-101.11 Mil. Ablynx NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2017 was %.


Ablynx NV EV-to-EBIT Historical Data

The historical data trend for Ablynx NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV EV-to-EBIT Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.50 -22.48 -14.23 84.72 -13.19

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.23 - 84.72 - -13.19

Competitive Comparison of Ablynx NV's EV-to-EBIT

For the Biotechnology subindustry, Ablynx NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ablynx NV's EV-to-EBIT falls into.



Ablynx NV EV-to-EBIT Calculation

Ablynx NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.971/-101.105
=-0.01

Ablynx NV's current Enterprise Value is €0.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2017 was €-101.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV  (XBRU:ABLXS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ablynx NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2017 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2017 ) =EBIT / Enterprise Value (Q: Dec. 2017 )
=-101.105/0
= %

Ablynx NV's Enterprise Value for the quarter that ended in Dec. 2017 was €0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2017 was €-101.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ablynx NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ablynx NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV (XBRU:ABLXS) Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines